Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EBITDA: 2021-2024

Historic EBITDA for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$314.7 million.

  • Amylyx Pharmaceuticals' EBITDA rose 52.38% to -$36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$157.3 million, marking a year-over-year increase of 42.18%. This contributed to the annual value of -$314.7 million for FY2024, which is 911.12% down from last year.
  • Amylyx Pharmaceuticals' EBITDA amounted to -$314.7 million in FY2024, which was down 911.12% from $38.8 million recorded in FY2023.
  • Amylyx Pharmaceuticals' EBITDA's 5-year high stood at $38.8 million during FY2023, with a 5-year trough of -$314.7 million in FY2024.
  • Over the past 3 years, Amylyx Pharmaceuticals' median EBITDA value was -$201.3 million (recorded in 2022), while the average stood at -$159.1 million.
  • In the last 5 years, Amylyx Pharmaceuticals' EBITDA surged by 119.27% in 2023 and then slumped by 911.12% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' EBITDA (Yearly) stood at -$82.7 million in 2021, then plummeted by 143.49% to -$201.3 million in 2022, then soared by 119.27% to $38.8 million in 2023, then tumbled by 911.12% to -$314.7 million in 2024.